Immunotherapy in non-small-cell lung cancer: a good start?
Mené sur 1 239 patients atteints d'un cancer du poumon non à petites cellules de stade III et non résécable, cet essai randomisé de phase III évalue, du point de vue de la survie globale, l'intérêt d'une immunothérapie d'entretien par técémotide après une chimioradiothérapie
The quest to develop improved treatments for patients with locally advanced non-small-cell lung cancer has been generally unfulfilling, despite sizable advances in radiotherapy technology and substantial progress in the understanding of tumour biology. Results from the recently reported phase 3 US Intergroup Trial (Radiation Therapy Oncology Group [RTOG ] 0617) 1 of standard-dose versus high-dose conformal chemoradiotherapy with or without cetuximab are particularly deflating...
The Lancet Oncology , commentaire, 2012